Archive for the ‘Anthrax vaccines’ Category
Emergent’s Fuad El-Hibri, an entrepreneur at heart
Posted by: fuadelhibri on April 2, 2012
Emergent BioSolutions Starts Phase I Clinical Trial for Third Generation Anthrax Vaccine
Posted by: fuadelhibri on January 5, 2011
Emergent BioSolutions Awarded HHS Contract Valued at up to $186.6 Million to Develop rPA Anthrax Vaccine
Posted by: fuadelhibri on September 20, 2010
Emergent BioSolutions Awarded NIAID Contract That Increases Potential Funding to Over $58 Million for Advanced Development of Third Generation Anthrax Vaccine
Posted by: fuadelhibri on September 10, 2010
Emergent Revises Upward 2010 Financial Forecast
Posted by: fuadelhibri on August 3, 2010
Emergent BioSolutions Awarded HHS Contract Valued at Up to $107 Million to Develop Large-Scale Manufacturing for BioThrax
Posted by: fuadelhibri on July 15, 2010
Emergent BioSolutions Hosts Biopreparedness Roundtable for NATO Parliamentarians
Posted by: fuadelhibri on July 13, 2010
Emergent BioSolutions Completes Deliveries of BioThrax to Allied Foreign Governments
Posted by: fuadelhibri on July 7, 2010
Emergent BioSolutions Inc. (EBS) CEO & Chairman, 10% Owner Fuad El-hibri sells 15,000 Shares
Posted by: fuadelhibri on August 17, 2009
